About Us

Curapath, is a global CDMO specialized in the tailored design, development, and GMP manufacturing of cutting-edge polymer and lipid-based drug delivery systems. Our customers benefit from our unique expertise, operational excellence and technical solutions in polymer (PNPs) and lipid nanoparticles (LNPs) along with their essential components.

In addition, we have extensive experience in drug conjugation and crosslinking, to increase stability, reduce toxicity, and enhance bioactivity.

At Curapath, we stand as your partner from discovery stages to commercial GMP scale-up. With our dedicated support, expertise, and state of the art manufacturing capabilities, we assure you a guaranteed path for your drug to navigate through clinical development and reach commercialization seamlessly.

Your success is our commitment.

Mission Statement

Through our development and manufacturing advanced solutions in non-viral drug delivery systems and polymer & lipid excipients, Curapath is making breakthrough innovations accessible to gene-therapy patients.

Vision Statement

Through innovation, Curapath is leading next generation of non-viral gene delivery to improve people’s lives.

Why Choose Us

At Curapath, nothing matters more to us than ensuring the complete customer satisfaction. We regularly launch satisfaction surveys among our valued customers. Our current Net Promoter Score (NPS) value is set at an astonishing 56, which means the global satisfaction level from the clients surveyed is very high. We continuously work hard to increase that number.

Meet Our Team

Philippe Clavel, PhD.
Chief Executive Officer

Philippe is the Chief Executive Officer of Curapath. He brings over 25 years of experience in chemical & pharmaceutical industry, with a specific focus on active pharmaceutical ingredient market (CDMO & Generics) and drug delivery solutions from R&D to commercial. Philippe has an extensive track record not only with regards to business development and the creation of trustful partnerships in Europe / US / Japan but also in process development, industrialization, and continuous improvement. Before joining Curapath, Philippe worked for 3 international companies with extensive development and manufacturing capabilities for pharmaceutical markets – Rhodia (now Solvay), Sanofi and Seqens – where he engaged and led global teams towards ambitious roadmaps and through challenging projects. For instance, Philippe was instrumental to secure the complex supply chain of oligosaccharides obtained by total synthesis and developed as animal free alternatives to heparinoids to treat thrombosis, to accelerate the installation of new manufacturing solutions for the hypertension market in Japan facing Fukushima crisis, to create new capacities for viral vectors manufacturing to face growing patients’ needs, and to establish the appropriate industrial scheme for supporting the worldwide commercial launch of a breakthrough therapy for amyotrophic lateral sclerosis. Philippe received two awards from Sanofi for his entrepreneurship and partnership achievements. He graduated from the Engineering School of Physics and Chemistry of Bordeaux (now ENSMAC), and obtained his PhD at University of Bordeaux, funded by EDF and Rhône-Poulenc/Rhodia, for which he was awarded best PhD thesis of French Chemical Society (SFC).

VICENT J. NEBOT, PhD.
Chief Technology Officer

Vicent is the Chief Technology Officer of Curapath. He brings more than 15 years of experience in the field of nanomaterials and drug delivery systems in both industry and academic settings, having co-authored more than 40 publications (including articles, book chapters and patents) in the field, and been awarded several grants as co-PI. Before his time at Curapath, he was Research Collaborator at Centro de Investigación Príncipe Felipe (CIPF). Vicent is an expert in polypeptide-based systems, soft materials, supramolecular chemistry, and physico-chemical characterization with a special focus on CMC development of drug nanomedicines and their regulatory aspects. Vicent obtained his Ph.D. degree in Chemistry and Material Science, funded by Procter & Gamble, from Universidad Jaume I de Castelló in 2012. After a post-doctoral period of 3 years at Polymer Therapeutics Laboratory, headed by Dr. Maria J. Vicent, Vicent joined PTS as a researcher awardee of Torres Quevedo Spanish Ministry Program. He also participated in MIT Sloan School of Management’s Entrepreneurship Development Program.

Nicolas Serra
Chief Financial Officer

Nicolas is the Chief Finacial Officer for Curapath. Nicolas is a seasoned financial executive with 15+ years of experience in dynamic and fast-paced environments across multiple sectors and countries. He started his career at PricewaterhouseCoopers Paris before joining DB Schenker Rail as Head of Finance & Accounting. More recently, he served as a Chief Financial Officer and Board Member of Telamon Shipping, Dragon Investors, Nice Tech, and MDCV. Nicolas has developed a deep understanding of financial reporting, budgeting, forecasting, and strategic planning and has acquired expertise in optimizing and automating processes to improve efficiency and reduce costs. In addition, he has extensive experience building and leading high-performing cross-functional teams, managing complex projects, driving change initiatives, and implementing best practices. Nicolas obtained his MSc in Business Administration at Kedge Business School in 2006.

AMADOR GARCÍA, PhD.
Director of Business Development

Amador is the Director of Business Development with more than 15 years of experience in working with and providing services to innovation companies across various sectors, including biotech, aerospace, aero-wind, petrochemical, and pharmaceutical industries. Over the past six years, he has held executive roles, where he has developed and implemented strategic plans to drive organizational growth, following a mission-driven approach and the EFQM model.
Before joining Curapath, Amador served as the Chief Technology Officer (CTO) at AIMPLAS, where he transitioned from technical and scientific roles to executive positions. Since 2019, he has been the Director of the Joint Research Unit UROPLAS, focused on promoting the use of polymeric materials for Drug Delivery and Regenerative Therapies in Urology (Fundación del Hospital General).
Since joining Curapath, Amador has played a pivotal role in creating and implementing the business development strategy. In his current role at Curapath, he leads the Sales and Business Development team, driving new business opportunities and guiding then organization’s strategic initiatives. Amador holds a bachelor’s degree in pharmacy and a PhD in Organic Chemistry. In 2010, he was honored with the Plastic and Innovation Award. Additionally, Amador has worked as an independent consultant in polymers and material science, collaborating with IT companies and food and beverage companies.

JOSE CONEJOS
Director of Operations

Jose is Operations Director at Curapath. Jose brings over 15 years of experience in the pharmaceutical field, working in Operations and Quality. He is a pharmacist with a Master’s degree in Pharmaceutical Industry and a Master’s in Biomedical Biotechnology. Before joining Curapath, he spent over five years as an inspector for the Spanish Health Authorities assessing the GMP compliance of commercial Drug Substances and Drug Products manufacturers. Since he joined Curapath, he has led the creation and implementation of the quality system from scratch, organized the manufacturing departments according to GMP standards, and led the construction of Curapath’s GMP facilities for both Drug Substances and Sterile Drug Products.

LAURA MORENO, PhD.
Director of Quality

Laura is the Quality Director and Qualified Person at Curapath. She is a trained Pharmacist and has a Ph.D. in Medicinal Chemistry. Laura has developed her career in the pharmaceutical industry with more than ten years of experience, first occupying R&D-related roles and progressing to positions specializing in GMP quality environments. Laura has expertise in managing GMP activities in Quality Control and Quality Assurance. She served as a Quality Control Specialist for third-party projects in Esteve Química, where she led projects from clinical stage Drug Substance through FDA marketing authorization. In addition, Laura acted as the Quality Assurance Manager at Laboratorios Edefarm, overseeing the manufacturing of commercial Drug Products. She joined Curapath in 2020, and manages the Quality Systems, and oversees the batch release of material manufactured at Curapath. Additionally, Laura hosts inspections and audits from regulatory Health Authorities and customers. Laura was instrumental in Curapath’s recent accreditation for GMP Investigational Drug Product manufacturing by the Spanish Agency for Medicine and Health Products (AEMPS). AEMPS is the regulatory agency that oversees the quality, safety, and efficacy of pharmaceuticals and medical devices in Spain and acts as a representative of the European Medicines Agency (EMA).

SERGIO ABAD, PhD.
Director of CMC

Sergio is the Chemistry, Manufacturing and Controls Director at Curapath. He is a chemist by training and holds a Ph.D. in organic chemistry. Sergio has over 15 years of experience in developing, validating, and transferring processes and analytical methods for new active ingredients(API) and drug products. In addition, he has developed his skills in producing novel radiopharmaceuticals and polymer-based products for clinical trials and in the methods to control the quality of these products. Sergio joined Curapath in 2016 as Quality Control Manager and was instrumental in the creation of Curapath’s Quality Control department and the building Curapath’s overall Quality Systems. Sergio supports our client’s therapeutic programs from early feasibility, overseeing clinical GMP manufacturing through process validation and commercial manufacturing.

AROA DURO, PhD.
Director of Research & Development

Aroa is a chemist by training and holds a PhD in Biochemistry and Biotechnology. She brings more than 10 years of experience in drug delivery and polymer science. She joined Curapath in 2021 as R&D manager. Aroa did her PhD at the CIPF in Valencia at the Polymer Therapeutics Lab self-funded with a fellowship from the national scheme. Then, she moved to the Molecular Bionics lab in UCL London for a postdoctoral experience, with first the competitive Newton International fellowship from the Royal Society of UK, and later with a Marie Curie fellowship from the European Commission. Her scientific background has provided her with vast experience in project management, supervising skills and successful grants applications. She counts with more than 30 publications including patents and research monographs. Aroa joined Curapath as a research awardee Torres Quevedo Spanish Ministry Program and since then, she has provided structure to the R&D Department to guarantee the continuous innovation of the company projects.

JUAN RUIZ
Director of Human Resources

Juan is Curapath’s HR Manager since 2022, he has more than 20 years of experience as an HR professional, mainly in companies in the industrial environment, in sectors such as: Chemicals, Automotive, Renewable Energies and Food, developing and leading HR departments with the implementation of policies and management tools, organizational transformation, always aligning with the needs of the business, he has also been a consultant with projects in which he has collaborated in restructuring, organizational changes and in the implementation of HR tools. At Curapath, he has created and developed the Human Resources/Health & Safety department, defining and directing the implementation of policies and tools for people management and occupational risk prevention.
Juan earned an MA in Organizational HR Management from ESIC Business School and a BA in Psychology from the University of Valencia.

JUAN JOSÉ ARROYO, PhD.
Director of PMO

Juan José is the Head of Project Management at Curapath. He is a trained chemist with a MSc. in Supramolecular Chemistry and a Ph.D. in Biochemistry and Biomedicine. He possesses +10 years in the development of nanomedicines and novel polymer-based drug delivery systems for multiple biomedical applications, including their physicochemical characterization and preclinical evaluation. He has authored +10 high impact publications in the field.
Juan José joined Curapath as Project Manager in early 2019 through a Torres Quevedo grant. Since then, he has accumulated an extensive experience in the management of complex projects in different stages of the clinical pathway.
As Head of Project Management, Juan José leads an interdisciplinary team of highly skilled Project Managers whose mission is to coordinate the operational internal teams to ensure efficient projects execution, while supporting business growth by efficient client’s relationship management. Additionally, Juan José manages several projects undergoing IND/IMPD applications and early clinical trials.

Contact Our Team